Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study - Concepedia

Concepedia

Publication | Open Access

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

DOI Full Paper Access

87

Citations

37

References

2023

Year

Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D. Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jérusalem, Seung Tae Kim, Keun‐Wook Lee,

Journal of Clinical Oncology

Abstract

Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.

References

	Year	Citations

Page 1